Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors

J Thorac Oncol. 2019 Aug;14(8):e157-e159. doi: 10.1016/j.jtho.2019.04.020. Epub 2019 May 7.

Authors

Affiliations

¹ Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
² Burning Rock Biotech, Guangzhou, China.
³ Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn.

PMID: 31075545
DOI: 10.1016/j.jtho.2019.04.020

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / pathology
Adult
ErbB Receptors / metabolism
Female
Humans
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors